Publications

Iwagami Y et al. Lambda phage-based vaccine induces antitumor immunity in hepatocellular carcinoma. Heliyon. 2017, PMID: 28971150

Details

Arab A et al. Lambda phage nanoparticles displaying HER2-derived E75 peptide induce effective E75-CD8+ T response. Immunol Res. 2018, PMID: 29143917

Details

Razazan A et al. Lambda bacteriophage nanoparticles displaying GP2, a HER2/neu derived peptide, induce prophylactic and therapeutic activities against TUBO tumor model in mice. Sci Rep. 2019, PMID: 30778090

Details

Ghaemi A et al. Recombinant lambda-phage nanobioparticles for tumor therapy in mice models. Genet Vaccines Ther. 2010, PMID: 20459865

Details

Bartolacci C, et al. Phage-Based Anti-HER2 Vaccination Can Circumvent Immune Tolerance against Breast Cancer [published correction appears in Cancer Immunol Res. 2019, PMID: 30327365

Details

Burtness B, et al. KEYNOTE-048 Investigators. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019, PMID: 31679945

Details

Ferris RL et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med. 2016, PMID: 27718784

Details

Mehra R et al. Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012. Br J Cancer. 2018 Jul, PMID: 29955135

Details

Ulivieri C et al. Antigenic properties of HCMV peptides displayed by filamentous bacteriophages vs. synthetic peptides. Immunol Lett. 2008, PMID: 18538862

Details

Sartorius R et al. Antigen delivery by filamentous bacteriophage fd displaying an anti-DEC-205 single-chain variable fragment confers adjuvanticity by triggering a TLR9-mediated immune response. EMBO Mol Med. 2015, PMID: 25888235

Details